Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Feb;150(2):327-36.
doi: 10.1111/j.1365-2133.2004.05712.x.

Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy

Affiliations

Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy

P Quaglino et al. Br J Dermatol. 2004 Feb.

Abstract

Background: Purine analogues [fludarabine monophosphate (FAMP); deoxycoformycin and 2-chlorodeoxyadenosine) and extracorporeal photochemotherapy (ECP) have been suggested to be active agents in advanced cutaneous T-cell lymphoma (CTCL) patients.

Objectives: To explore further the clinical efficacy and safety of FAMP monochemotherapy in advanced CTCL and to evaluate if the sequential association of ECP to FAMP in selected patients may improve the response rate (RR) and/or lengthen the remission duration.

Patients and methods: Forty-four CTCL patients [17 Sézary syndrome (SS); 26 mycosis fungoides (MF), stage IIB-IV or with peripheral blood involvement; one MF associated with lymphomatoid papulosis (LyP)] were enrolled in this pilot cohort study. All the patients received FAMP 25 mg m(-2) 5 days monthly; 19 patients (43.2%) underwent ECP after FAMP was discontinued. The majority of patients with erythrodermic CTCL or peripheral blood involvement underwent the combined FAMP-ECP schedule.

Results: After a median follow-up of 4.2 years, the overall FAMP RR was 29.5% (13/44); a higher RR was obtained in SS (35.3%) than in MF patients (25.9%). According to the treatment group, the RR of the FAMP-ECP group (63.2%) was significantly higher than that of the FAMP monotherapy group (24%; P=0.021). No statistically significant difference was found in time-to-progression (TTP) or survival by therapy group, even if the TTP of the patients treated with the FAMP-ECP combination therapy was higher (median 13 vs. 7 months). A decrease or a normalization in the CD4+CD26- circulating subset was observed in responding patients, paralleling the reduction in the circulating Sézary cells.

Conclusions: FAMP confirms its clinical activity as a single agent in SS; conversely, FAMP results do not compare favourably with other therapeutic approaches for advanced stage MF patients. The sequential association of ECP after FAMP seems to increase the RR, even if future randomized studies are needed to confirm these results.

PubMed Disclaimer

Similar articles

Cited by

  • Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.
    Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD. Capriotti E, et al. Leuk Lymphoma. 2008 Jun;49(6):1190-201. doi: 10.1080/10428190802064917. Leuk Lymphoma. 2008. PMID: 18569641 Free PMC article.
  • Clinical Results of Extracorporeal Photopheresis.
    Worel N, Leitner G. Worel N, et al. Transfus Med Hemother. 2012 Aug;39(4):254-262. doi: 10.1159/000341811. Epub 2012 Jul 26. Transfus Med Hemother. 2012. PMID: 22969695 Free PMC article.
  • European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.
    Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. Knobler R, et al. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2693-2716. doi: 10.1111/jdv.16890. Epub 2020 Oct 6. J Eur Acad Dermatol Venereol. 2020. PMID: 33025659 Free PMC article.
  • Guidelines on the use of extracorporeal photopheresis.
    Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, Ludvigsson J, Quaglino P, Reinisch W, Scarisbrick J, Schwarz T, Wolf P, Arenberger P, Assaf C, Bagot M, Barr M, Bohbot A, Bruckner-Tuderman L, Dreno B, Enk A, French L, Gniadecki R, Gollnick H, Hertl M, Jantschitsch C, Jung A, Just U, Klemke CD, Lippert U, Luger T, Papadavid E, Pehamberger H, Ranki A, Stadler R, Sterry W, Wolf IH, Worm M, Zic J, Zouboulis CC, Hillen U. Knobler R, et al. J Eur Acad Dermatol Venereol. 2014 Jan;28 Suppl 1(Suppl 1):1-37. doi: 10.1111/jdv.12311. J Eur Acad Dermatol Venereol. 2014. PMID: 24354653 Free PMC article.
  • Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat. Medical Advisory Secretariat. Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1. Ont Health Technol Assess Ser. 2006. PMID: 23074497 Free PMC article.

MeSH terms